<DOC>
	<DOCNO>NCT00076011</DOCNO>
	<brief_summary>The primary purpose protocol determine activity AG 013736 patient metastatic renal cell cancer receive 1 prior cytokine-based therapy .</brief_summary>
	<brief_title>Anti-angiogenesis Agent AG-013736 Patients With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Histologically document RCC metastasis . Failure 1 prior cytokinebased therapy ( interleukin2 and/or interferon ) due disease progression unacceptable treatmentrelated toxicity Any prior systemic treatment Renal Cell Carcinoma [ RCC ] 1 prior cytokinebased treatment regimen . Cytokinebased regimen contain thalidomide antiangiogenesis agent allow . Inability take oral medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>